BeiGene

BeiGene

BeiGene

BeiGene is a Chinese life sciences biotechnology company based in Beijing that is focused on discovering and developing innovative oncology drugs that will address unmet medical needs in cancers that are prevalent in China and the AsiaPacific region..
Type
B2c
Founded
2010
Raised
$185M
Follow us
Alexa global traffic share
Latest funding
$185,000,000
Post-IPO equity - 2016
Team Size
50+
Employees
Location
Headquarters
Xconomy

Amgen Doubles Down on BeiGene Collaboration, Investing $421M More

DealStreetAsia

HK, Nasdaq-listed Chinese biotech firm BeiGene to raise $2.08b in share sale

Bloomberg Technology

Chinese Biotech Beigene to Raise $2.1 Billion in Share Sale

MedCity News

BeiGene reports positive Phase III interim analysis for lung cancer drug

Xconomy

Celgene Builds Up Cancer Drug Pipeline With BeiGene Deal

Health
$185,000,000 Post-IPO equity
Seeking Alpha

Week In Review: Beijing's BeiGene Raises $185 Million For Clinical Trial Program